ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 182 filers reported holding ASCENDIS PHARMA A/S in Q1 2022. The put-call ratio across all filers is 0.64 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $516,799 | +3.1% | 5,519 | -1.7% | 0.01% | +10.0% |
| Q2 2023 | $501,317 | -20.6% | 5,617 | -4.6% | 0.01% | -23.1% |
| Q1 2023 | $631,204 | -15.8% | 5,887 | -4.1% | 0.01% | -13.3% |
| Q4 2022 | $750,000 | -54.1% | 6,141 | -61.2% | 0.02% | -55.9% |
| Q3 2022 | $1,633,000 | +4.9% | 15,816 | -5.6% | 0.03% | +13.3% |
| Q2 2022 | $1,557,000 | -20.9% | 16,749 | -0.1% | 0.03% | 0.0% |
| Q1 2022 | $1,968,000 | -10.0% | 16,771 | +3.2% | 0.03% | -3.2% |
| Q4 2021 | $2,186,000 | -7.4% | 16,251 | +9.7% | 0.03% | -13.9% |
| Q3 2021 | $2,360,000 | +19.4% | 14,808 | -1.4% | 0.04% | +24.1% |
| Q2 2021 | $1,976,000 | +11.3% | 15,020 | +9.0% | 0.03% | +3.6% |
| Q1 2021 | $1,776,000 | +25.1% | 13,780 | +61.9% | 0.03% | +21.7% |
| Q4 2020 | $1,420,000 | +100.3% | 8,513 | +85.2% | 0.02% | +76.9% |
| Q3 2020 | $709,000 | +18.8% | 4,597 | +13.9% | 0.01% | +8.3% |
| Q2 2020 | $597,000 | +295.4% | 4,037 | +200.4% | 0.01% | +200.0% |
| Q1 2020 | $151,000 | – | 1,344 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 10,719,555 | $1,003,779,130 | 19.76% |
| Q Global Advisors, LLC | 285,000 | $26,687 | 17.16% |
| Finepoint Capital LP | 163,772 | $15,335,610 | 7.64% |
| Avoro Capital Advisors LLC | 3,670,000 | $343,658,800 | 5.36% |
| Spyglass Capital Management LLC | 614,618 | $57,552,830 | 4.51% |
| Sofinnova Investments, Inc. | 754,032 | $70,607,556 | 4.45% |
| Saturn V Capital Management LP | 112,473 | $10,531,972 | 4.41% |
| DAFNA Capital Management LLC | 136,212 | $12,754,892 | 3.97% |
| ARS Investment Partners, LLC | 285,918 | $26,773,362 | 3.32% |
| Ghost Tree Capital, LLC | 85,000 | $7,959,400 | 2.62% |